Abstract
-
Int J Mol Sci. 2025 Jan 2;26(1):338. doi: 10.3390/ijms26010338.
Data Mining Approach to Melatonin Treatment in Alzheimer’s Disease: New Gene Targets MMP2 and NR3C1.
Zhang J(1)(2)(3), Tsui KC(1)(2)(3), Lee HY(3), Aquili L(1)(2)(4), Wong KH(5), Kocabicak E(6), Temel Y(7), Lu Z(1)(8), Fung ML(3), Kalueff A(1)(2), Lim LW(1)(2)(6)(7)(8).
Author information: (1)Department of Biosciences and Bioinformatics, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou 215123, China. (2)Suzhou Municipal Key Laboratory of Neurobiology and Cell Signaling, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou 215123, China. (3)School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. (4)College of Science, Health, Engineering and Education, Discipline of Psychology, Murdoch University, Perth 6150, Australia. (5)Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia. (6)Atlas University, 34406 Istanbul, Turkey. (7)Department of Neurosurgery, Maastricht University, 6202 Maastricht, The Netherlands. (8)Suzhou Municipal Key Laboratory of Cancer Biology and Chronic Diseases, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou 215123, China.
Melatonin is a hormone released by the pineal gland that regulates the sleep-wake cycle. It has been widely studied for its therapeutic effects on Alzheimer’s disease (AD), particularly through the amyloidosis, oxidative stress, and neuroinflammation pathways. Nevertheless, the mechanisms through which it exerts its neuroprotective effects in AD are still largely unknown. Data mining was used to identify potential gene targets that link melatonin’s effects to AD pathways, yielding a comprehensive view of the underlying molecular mechanisms. We identified 3397 genes related to AD from DisGeNet and 329 melatonin gene targets from ChEMBL, which revealed 223 overlapping genes and the potential shared pathways. Thes